Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at ...
CARDIOTTRansform missed its primary endpoint, but its secondary analysis of eplontersen in ATTR-CM patients on background ...
Mechanical thrombectomy for STEMI with large thrombus burden reduced infarct size by 26% in the NATURE trial, meeting its ...
FDA's July 2026 approval of at-home subcutaneous lecanemab initiation eliminates the 18-month IV requirement, reshaping CNS ...
Cumberland Pharmaceuticals seeks FDA action on ifetroban DMD data from an ongoing extension study, positioning the drug for ...
How Ocular engineered a retinal drug program backward from approval, and what that means for every sponsor still designing ...
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring ...
AusperBio closes $120M Series C for AHB-137 Hepatitis B program showing 70% functional cure rate in Phase 2 trial data.
MBX Biosciences has dosed the first patient in the Phase 3 canvuparatide trial for hypoparathyroidism, a 160-patient pivotal ...
AbbVie seeks EMA approval for SKYRIZI subcutaneous induction in Crohn's disease following Phase 3 AFFIRM trial success.
SOC vs RES is decided cell by cell in the visit grid, not procedure by procedure. Here is what that means when an auditor ...
Caliway's Phase 3 SUPREME-01 trial for CBL-514 now enrolling patients. The pivotal study evaluates abdominal fat reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results